BMS to Present P-II Study Results of BMS-986278 for Progressive Pulmonary Fibrosis at ERS 2023
- The P-II study evaluating BMS-986278 (LPA1 antagonist) vs PBO for 26wks. in 278 patients, showed that patients treated with BMS-986278 (30 & 60mg, BID) achieved a 69% & 42% reduction in the rate of decline in percent predicted forced vital capacity (ppFVC) in the while-on-treatment analysis; 74% & 37% relative reduction in the treatment policy analysis
- In both dose groups, the treatment effect was consistent in the presence or absence of background antifibrotics (38% & 36% vs 41%) and usual interstitial pneumonia (UIP) pattern (55% & 50% vs 51%), respectively
- The therapy was well tolerated in both treatment arms, and the rate of AEs was similar to PBO, AEs (83% & 67% vs 78%), serious AEs (10% & 12% vs 32%), AEs leading to treatment discontinuation rates (3% & 0% vs 15%), respectively
Ref: BMS | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.